FDA plans meeting for paediatric review of four anticancers
This article was originally published in Scrip
Executive Summary
The US FDA's paediatric oncology subcommittee of the oncologic drugs advisory committee will meet on 30 November to review paediatric development plans for four products that were either recently approved by the agency or are in late-stage development for an adult oncology indication.